Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four

Priyanka Gandhi¹, Nasiq Hasan¹, Korrina Gidwani², Jonathan Yang², Jessica Cao³, Stanley Saju³, Charles C Wykoff³, Samer Khateb⁴, Min Kim⁵, Ninan Jacob⁶, Yusuf Ashfaq⁷, Zachary Kroeger⁷, Micheal Zhang^{8

9}, Peranut Chotcomwongse¹⁰, Paisan Ruamviboonsuk¹⁰, Halit Winter¹¹, Manjot Gill¹¹, Luiz H Lima¹², Lihteh Wu¹³, Jay Chhablani^{14

15}; Macula Society International CSCR Research Network – MICRoN, MICRoN study group

Collaborators, Affiliations

Collaborators

Macula Society International CSCR Research Network – MICRoN, MICRoN study group:
Carmen Antia, Luis Aria Barquet, Elodie Bousquet, Lisa Checchin, Andrea Corletti, Lorenzo Ferro Desideri, Adrain Fung, Adarsh Gadari, Utkarsh Doshi, Sunir Garg, Giulia Gregori, Felicia Hertkorn, Naoya Imanaga, Rahul N Khurana, Hideki Koizumi, Timothy Lai, Marco Lupidi, Bita Momenaei, Marion R Munk, Roselind Ni, Maurizio Battaglia Parodi, Gabriele Piccoli, Lorenzo Pili, Francisco Rodriguez, Elizabeth Rossin, Niroj Kumar Sahoo, Priya Shah, Rufino Silva, Panisa Singhanetr, Kent Small, Lucia Sobrin, Carol Villafeurte, Stela Vujosevic, Jay Wang, Glenn Yiu, Arman Zarnegar, Kiran K Vupparaboina

Affiliations

¹ Department of Ophthalmology, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA.
² University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
³ Retina Consultants of Texas, Houston, TX, USA.
⁴ Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
⁵ Yonsei University College of Medicine, 211 Eonjuro, Gangnam-Gu, Seoul, 06273, Republic of Korea.
⁶ Department of Retina and Vitreous, L V Prasad Eye Institute, Vijayawada, India.
⁷ Casey Eye Institute at Oregon Health and Science University, 515 SW Campus Dr., Portland, OR, USA.
⁸ The Canberra Hospital, Yamba Dr, Garran, ACT 2605, Australia.
⁹ Sydney and Sydney Eye Hospital, 8 Macquarie St, Sydney, NSW, 200, Australia.
¹⁰ Vitreoretina Unit, Department of Ophthalmology, Rajavithi Hospital, Rungsit University, Bangkok, Thailand.
¹¹ Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
¹² Department of Ophthalmology, Federal University of São Paulo/Paulista School of Medicine, São Paulo, Brazil.
¹³ Asociados de Macula Vitreo y Retina de Costa Rica, San José, Costa Rica.
¹⁴ Department of Ophthalmology, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA. jay.chhablani@gmail.com.
¹⁵ University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. jay.chhablani@gmail.com.

PMID: 41074999
DOI: 10.1007/s00417-025-06969-5

Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four

Priyanka Gandhi et al. Graefes Arch Clin Exp Ophthalmol. 2025.

. 2025 Oct 11.

doi: 10.1007/s00417-025-06969-5. Online ahead of print.

Authors

Collaborators

Macula Society International CSCR Research Network – MICRoN, MICRoN study group:
Carmen Antia, Luis Aria Barquet, Elodie Bousquet, Lisa Checchin, Andrea Corletti, Lorenzo Ferro Desideri, Adrain Fung, Adarsh Gadari, Utkarsh Doshi, Sunir Garg, Giulia Gregori, Felicia Hertkorn, Naoya Imanaga, Rahul N Khurana, Hideki Koizumi, Timothy Lai, Marco Lupidi, Bita Momenaei, Marion R Munk, Roselind Ni, Maurizio Battaglia Parodi, Gabriele Piccoli, Lorenzo Pili, Francisco Rodriguez, Elizabeth Rossin, Niroj Kumar Sahoo, Priya Shah, Rufino Silva, Panisa Singhanetr, Kent Small, Lucia Sobrin, Carol Villafeurte, Stela Vujosevic, Jay Wang, Glenn Yiu, Arman Zarnegar, Kiran K Vupparaboina

Affiliations

¹ Department of Ophthalmology, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA.
² University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
³ Retina Consultants of Texas, Houston, TX, USA.
⁴ Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
⁵ Yonsei University College of Medicine, 211 Eonjuro, Gangnam-Gu, Seoul, 06273, Republic of Korea.
⁶ Department of Retina and Vitreous, L V Prasad Eye Institute, Vijayawada, India.
⁷ Casey Eye Institute at Oregon Health and Science University, 515 SW Campus Dr., Portland, OR, USA.
⁸ The Canberra Hospital, Yamba Dr, Garran, ACT 2605, Australia.
⁹ Sydney and Sydney Eye Hospital, 8 Macquarie St, Sydney, NSW, 200, Australia.
¹⁰ Vitreoretina Unit, Department of Ophthalmology, Rajavithi Hospital, Rungsit University, Bangkok, Thailand.
¹¹ Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
¹² Department of Ophthalmology, Federal University of São Paulo/Paulista School of Medicine, São Paulo, Brazil.
¹³ Asociados de Macula Vitreo y Retina de Costa Rica, San José, Costa Rica.
¹⁴ Department of Ophthalmology, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA. jay.chhablani@gmail.com.
¹⁵ University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. jay.chhablani@gmail.com.

PMID: 41074999
DOI: 10.1007/s00417-025-06969-5

Abstract

Purpose: While central serous chorioretinopathy (CSCR) frequently resolves after the first episode, in 30-50% of cases, subretinal fluid (SRF) persists and can substantially impair vision. To identify persistence predictors, this study compared demographic, clinical, and imaging data between patients with resolution and SRF persistence.

Methods: Retrospective data were collected at baseline and follow-up from 308 eyes of 295 patients with CSCR in collaboration with the Macula Society CSCR Study Group. Patients were divided into a resolved (RG) and a persistent CSCR group (PG). Patients with known recurrence after resolution were excluded. Optical coherence tomography (OCT) biomarkers including central macular thickness (CMT), subfoveal choroidal thickness (SFCT), neurosensory detachment height (NSD), Haller layer thickness, inner choroidal thickness (ICT), and choroidal vascularity index (CVI) were analysed.

Results: PG had 148 eyes and RG had 160 eyes. Mean age in PG vs RG was 47.62 ± 11.63 vs. 44.89 ± 10.12 years (p = 0.029). Mean presenting symptom duration was significantly greater in PG than RG (8.67 ± 23.33 vs. 4.33 ± 31.18 months) (p = 0.005). There was a higher frequency of complex cases (21.6%) in PG (p < 0.001). Baseline mean CMT (358.11 ± 157.02 microns) and NSD height (175.78 ± 134.34 microns) were significantly lower in PG (p = 0.007). Multivariate logistic regression analysis showed that each additional year of age was associated with a 22.3% increase in the odds of having persistent SRF.

Conclusion: Age at presentation, symptom duration, baseline CMT and NSD height may serve as practical risk stratifiers to identify eyes at high risk for chronicity in CSCR.

Key messages: What is known Delayed presentation and absence of early therapy predispose eyes to chronic CSCR. SFCT plays a predictive role in persistent CSCR. What is new Age at presentation is a significant predictor of persistent SRF. Baseline CMT and NSD height may serve as practical risk stratifiers to identify eyes at high risk for chronicity.

Keywords: CMT; NSD; OCT; Persistent CSCR.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of each centre: University of Pittsburgh, Hebrew University of Jerusalem, Yonsei University College of Medicine, L V Prasad Eye Institute, Casey Eye Institute at Oregon Health and Science University, Rungsit University, Northwestern University Feinberg School of Medicine, Federal University of São Paulo and Asociados de Macula Vitreo y Retina de Costa Rica. Research involving human participants and/or animals: This is a retrospective study involving patient data. Informed consent: A “waiver of informed consent” was obtained considering the retrospective nature of the study. Disclosure of potential conflicts of interest: The authors have no conflict of interest.

References

1. Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126 - DOI - PubMed - PMC
1. Van Rijssen TJ et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770 - DOI - PubMed
1. Fung AT, Yang Y, Kam AW (2023) Central serous chorioretinopathy: a review. Clin Exp Ophthalmol 51:243–270 - DOI - PubMed
1. Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, Bartollino S, Costagliola C (2019) Central serous chorioretinopathy: pathogenesis and management. Clin Ophthalmol 13:2341–2352. https://doi.org/10.2147/OPTH.S220845
1. Chan W-M et al (2008) Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28:85–93 - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Springer
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four

Collaborators

Affiliations

Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources

Miscellaneous